These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


240 related items for PubMed ID: 9205766

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparative study of the safety and efficacy of ebrotidine versus ranitidine and placebo in the prevention of piroxicam-induced gastroduodenal lesions.
    Puscas I, Puscas C, Coltau M, Pasca R, Torres J, Márquez M, Herrero E, Fillat O, Ortiz JA.
    Arzneimittelforschung; 1997 Apr; 47(4A):568-72. PubMed ID: 9205767
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Anti-Helicobacter pylori activities of ebrotidine. A review of biochemical and animal experimental studies and data.
    Slomiany BL, Piotrowski J, Slomiany A.
    Arzneimittelforschung; 1997 Apr; 47(4A):475-82. PubMed ID: 9205747
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of ebrotidine and ranitidine in the treatment of benign gastric ulcer.
    Gedliczka O, Bobrzynski A, Rembiasz K, Fillat O, Torres J, Herrero E, Márquez M, Camps F, Ortiz JA.
    Arzneimittelforschung; 1997 Apr; 47(4A):560-4. PubMed ID: 9205765
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of the efficacy and safety of ebrotidine in the treatment of duodenal ulcer. A multicentre, double-blind, placebo-controlled phase II study.
    Gabryelewicz A, Czajkowski A, Skrodzka D, Marlicz K, Luca de Tena F, Aldeguer M, Chantar C, Márquez M, Torres J, Ortiz JA.
    Arzneimittelforschung; 1997 Apr; 47(4A):545-50. PubMed ID: 9205762
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Involvement of endogenous nitric oxide and sulfhydryl compounds in ebrotidine-induced gastroprotection.
    Palop D, Conejo L, Sacristán A, Ortiz JA.
    Arzneimittelforschung; 1997 Apr; 47(4A):468-71. PubMed ID: 9205745
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Study on the increment of the amount of gastric mucus in rats after repeated-dose administration of ebrotidine.
    Romero A, Villamayor F, Palop D, Falcó J, Sacristán A, Ortiz JA.
    Arzneimittelforschung; 1997 Apr; 47(4A):455-8. PubMed ID: 9205743
    [Abstract] [Full Text] [Related]

  • 16. Prevention of non-steroidal anti-inflammatory agents induced acute gastric mucosal lesions by carbonic anhydrase inhibitors. An endoscopic study.
    Puscas I, Hajdu A, Buzás G, Bernáth Z.
    Acta Physiol Hung; 1989 Apr; 73(2-3):279-83. PubMed ID: 2596317
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Gastroprotective and ulcer-healing activities of a new H2-receptor antagonist: ebrotidine.
    Brzozowski T, Majka J, Konturek SJ.
    Digestion; 1992 Apr; 51(1):27-36. PubMed ID: 1353465
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 12.